{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T03:00:41Z","timestamp":1767841241318,"version":"3.49.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["GA 115861"],"award-info":[{"award-number":["GA 115861"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union Horizon 2020 Framework Programme for Research and Innovation"},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vaccine Research Institute","award":["ANR-10-LABX-77-0"],"award-info":[{"award-number":["ANR-10-LABX-77-0"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The EBL2001 phase 2 trial tested the 2-dose Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine in Europe. Safety and humoral immunogenicity assessments led to European Union market authorization in 2020. Complementary analyses of immune responses are warranted to better characterize vaccine effects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted an ancillary study to analyze changes in the serum and cellular responses. Serum biomarkers of activation\/inflammation were evaluated using a Luminex assay. Vaccine-elicited T-cell responses and functions were evaluated by assessing their phenotype, cytokine production, proliferation, and cytotoxic potential. Integrated data analysis was performed through correlation and principal component analysis of serum biomarkers and cellular immune responses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Forty-eight volunteers were included. The Ad26.ZEBOV, MVA-BN-Filo vaccine elicited (1) serum increase of inflammatory\/activation markers mainly at 1 day after the Ad26.ZEBOV vaccine; and (2) durable EBOV-specific T-cell proliferation and CD8+ T cells exhibiting a cytotoxic phenotype after Ad26.ZEBOV prime, after MVA-BN-Filo boost, and 6 months postvaccination. Integrated analysis revealed correlations between (1) EBOV-specific CD8+ T-cell proliferation and cytotoxic phenotype; and (2) high EBOV-specific CD8+ T-cell cytotoxic phenotype and low inflammatory marker IL-8 at day 1 postvaccination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>This study provides unique insights into the in vivo contribution of proliferation\/cytotoxic CD8+ T cells and inflammation to the Ad26.ZEBOV, MVA-BN-Filo vaccine-induced potency.<\/jats:p>\n                  <jats:p>Clinical Trials Registration. NCT02416453.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiae360","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T22:14:00Z","timestamp":1720822440000},"page":"230-240","source":"Crossref","is-referenced-by-count":1,"title":["Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial"],"prefix":"10.1093","volume":"231","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6925-0225","authenticated-orcid":false,"given":"Christine","family":"Lacabaratz","sequence":"first","affiliation":[{"name":"Vaccine Research Institute , Cr\u00e9teil ,","place":["France"]},{"name":"INSERM Unit\u00e9 U955, Institut Mondor de Recherche Biom\u00e9dicale (IMRB) , Cr\u00e9teil ,","place":["France"]},{"name":"Facult\u00e9 de M\u00e9decine, Universit\u00e9 Paris-Est , Cr\u00e9teil ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lany","family":"Durand","sequence":"additional","affiliation":[{"name":"Vaccine Research Institute , Cr\u00e9teil ,","place":["France"]},{"name":"Population Health Research Center, Universit\u00e9 Bordeaux, INSERM UMR 1219, Statistics in System Biology and Translational Medicine (SISTM), Institut national de recherche en sciences et technologies du num\u00e9rique (INRIA) , Bordeaux ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Wiedemann","sequence":"additional","affiliation":[{"name":"Vaccine Research Institute , Cr\u00e9teil ,","place":["France"]},{"name":"INSERM Unit\u00e9 U955, Institut Mondor de Recherche Biom\u00e9dicale (IMRB) , Cr\u00e9teil ,","place":["France"]},{"name":"Facult\u00e9 de M\u00e9decine, Universit\u00e9 Paris-Est , Cr\u00e9teil ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emile","family":"Foucat","sequence":"additional","affiliation":[{"name":"Vaccine Research Institute , Cr\u00e9teil ,","place":["France"]},{"name":"INSERM Unit\u00e9 U955, Institut Mondor de Recherche Biom\u00e9dicale (IMRB) , Cr\u00e9teil ,","place":["France"]},{"name":"Facult\u00e9 de M\u00e9decine, Universit\u00e9 Paris-Est , Cr\u00e9teil ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Sur\u00e9naud","sequence":"additional","affiliation":[{"name":"Vaccine Research Institute , Cr\u00e9teil ,","place":["France"]},{"name":"INSERM Unit\u00e9 U955, Institut Mondor de Recherche Biom\u00e9dicale (IMRB) , Cr\u00e9teil ,","place":["France"]},{"name":"Facult\u00e9 de M\u00e9decine, Universit\u00e9 Paris-Est , Cr\u00e9teil ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Krief","sequence":"additional","affiliation":[{"name":"Vaccine Research Institute , Cr\u00e9teil ,","place":["France"]},{"name":"INSERM Unit\u00e9 U955, Institut Mondor de Recherche Biom\u00e9dicale (IMRB) , Cr\u00e9teil ,","place":["France"]},{"name":"Facult\u00e9 de M\u00e9decine, Universit\u00e9 Paris-Est , Cr\u00e9teil ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Guillaumat","sequence":"additional","affiliation":[{"name":"Vaccine Research Institute , Cr\u00e9teil ,","place":["France"]},{"name":"INSERM Unit\u00e9 U955, Institut Mondor de Recherche Biom\u00e9dicale (IMRB) , Cr\u00e9teil ,","place":["France"]},{"name":"Facult\u00e9 de M\u00e9decine, Universit\u00e9 Paris-Est , Cr\u00e9teil ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Robinson","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Prevention \u00a0 B.V., Leiden ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Luhn","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Prevention \u00a0 B.V., Leiden ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viki","family":"Bockstal","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Prevention \u00a0 B.V., Leiden ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolphe","family":"Thi\u00e9baut","sequence":"additional","affiliation":[{"name":"Vaccine Research Institute , Cr\u00e9teil ,","place":["France"]},{"name":"Population Health Research Center, Universit\u00e9 Bordeaux, INSERM UMR 1219, Statistics in System Biology and Translational Medicine (SISTM), Institut national de recherche en sciences et technologies du num\u00e9rique (INRIA) , Bordeaux ,","place":["France"]},{"name":"Department of Medical Information and CIC-EC 1401\/Euclid F-CRIN, Centre Hospitalier Universitaire de Bordeaux , Bordeaux ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7682-2225","authenticated-orcid":false,"given":"Laura","family":"Richert","sequence":"additional","affiliation":[{"name":"Vaccine Research Institute , Cr\u00e9teil ,","place":["France"]},{"name":"Population Health Research Center, Universit\u00e9 Bordeaux, INSERM UMR 1219, Statistics in System Biology and Translational Medicine (SISTM), Institut national de recherche en sciences et technologies du num\u00e9rique (INRIA) , Bordeaux ,","place":["France"]},{"name":"Department of Medical Information and CIC-EC 1401\/Euclid F-CRIN, Centre Hospitalier Universitaire de Bordeaux , Bordeaux ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5549-6256","authenticated-orcid":false,"given":"Yves","family":"L\u00e9vy","sequence":"additional","affiliation":[{"name":"Vaccine Research Institute , Cr\u00e9teil ,","place":["France"]},{"name":"INSERM Unit\u00e9 U955, Institut Mondor de Recherche Biom\u00e9dicale (IMRB) , Cr\u00e9teil ,","place":["France"]},{"name":"Facult\u00e9 de M\u00e9decine, Universit\u00e9 Paris-Est , Cr\u00e9teil ,","place":["France"]},{"name":"Service d\u2019Immunologie Clinique, Groupe Henri-Mondor Albert-Chenevier, Assistance Publique-H\u00f4pitaux de Paris , Cr\u00e9teil ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,7,16]]},"reference":[{"key":"2025020417125878000_jiae360-B1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"2025020417125878000_jiae360-B2","doi-asserted-by":"crossref","first-page":"e055596","DOI":"10.1136\/bmjopen-2021-055596","article-title":"Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo","volume":"12","author":"Watson-Jones","year":"2022","journal-title":"BMJ Open"},{"key":"2025020417125878000_jiae360-B3","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"key":"2025020417125878000_jiae360-B4","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jama.2016.20644","article-title":"Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara-vectored Ebola vaccines at 1 year","volume":"317","author":"Winslow","year":"2017","journal-title":"JAMA"},{"key":"2025020417125878000_jiae360-B5","doi-asserted-by":"crossref","first-page":"e0192312","DOI":"10.1371\/journal.pone.0192312","article-title":"A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates","volume":"13","author":"Callendret","year":"2018","journal-title":"PLoS One"},{"key":"2025020417125878000_jiae360-B6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/infdis\/jiz071","article-title":"Safety and immunogenicity of a 2-dose heterologous vaccine regimen with Ad26.ZEBOV and MVA-BN-filo Ebola vaccines: 12\u2013month data from a phase 1 randomized clinical trial in Nairobi, Kenya","volume":"220","author":"Mutua","year":"2019","journal-title":"J Infect Dis"},{"key":"2025020417125878000_jiae360-B7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/infdis\/jiz070","article-title":"Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Uganda and Tanzania","volume":"220","author":"Anywaine","year":"2019","journal-title":"J Infect Dis"},{"key":"2025020417125878000_jiae360-B8","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1473-3099(20)30476-X","article-title":"Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial","volume":"21","author":"Pollard","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2025020417125878000_jiae360-B9","doi-asserted-by":"crossref","first-page":"e1003813","DOI":"10.1371\/journal.pmed.1003813","article-title":"Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: a randomised, placebo-controlled phase II clinical trial in Africa","volume":"18","author":"Barry","year":"2021","journal-title":"PLoS Med"},{"key":"2025020417125878000_jiae360-B10","doi-asserted-by":"crossref","first-page":"e1003865","DOI":"10.1371\/journal.pmed.1003865","article-title":"Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: a randomised, placebo-controlled, multicentre phase II clinical trial","volume":"19","author":"Anywaine","year":"2022","journal-title":"PLoS Med"},{"key":"2025020417125878000_jiae360-B11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41541-021-00280-0","article-title":"Durable natural killer cell responses after heterologous two-dose Ebola vaccination","volume":"6","author":"Wagstaffe","year":"2021","journal-title":"NPJ Vaccines"},{"key":"2025020417125878000_jiae360-B12","doi-asserted-by":"crossref","first-page":"112711","DOI":"10.1016\/j.jim.2019.112711","article-title":"Analyzing cellular immunogenicity in vaccine clinical trials: a new statistical method including non-specific responses for accurate estimation of vaccine effect","volume":"477","author":"Lhomme","year":"2020","journal-title":"J Immunol Methods"},{"key":"2025020417125878000_jiae360-B13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Statist Soc B"},{"key":"2025020417125878000_jiae360-B14","doi-asserted-by":"crossref","first-page":"eaaj1701","DOI":"10.1126\/scitranslmed.aaj1701","article-title":"A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa","volume":"9","author":"Huttner","year":"2017","journal-title":"Sci Transl Med"},{"key":"2025020417125878000_jiae360-B15","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.celrep.2017.08.023","article-title":"Systems vaccinology identifies an early innate immune signature as a correlate of antibody responses to the Ebola vaccine rVSV-ZEBOV","volume":"20","author":"Rechtien","year":"2017","journal-title":"Cell Rep"},{"key":"2025020417125878000_jiae360-B16","doi-asserted-by":"crossref","first-page":"27944","DOI":"10.1038\/srep27944","article-title":"Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine","volume":"6","author":"Farooq","year":"2016","journal-title":"Sci Rep"},{"key":"2025020417125878000_jiae360-B17","doi-asserted-by":"crossref","first-page":"113101","DOI":"10.1016\/j.celrep.2023.113101","article-title":"Identification of early gene expression profiles associated with long-lasting antibody responses to the Ebola vaccine Ad26.ZEBOV\/MVA-BN-Filo","volume":"42","author":"Blengio","year":"2023","journal-title":"Cell Rep"},{"key":"2025020417125878000_jiae360-B18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ebiom.2017.03.045","article-title":"Dose-dependent T-cell dynamics and cytokine cascade following rVSV-ZEBOV immunization","volume":"19","author":"Dahlke","year":"2017","journal-title":"EBioMedicine"},{"key":"2025020417125878000_jiae360-B19","doi-asserted-by":"crossref","first-page":"e00579-19","DOI":"10.1128\/JVI.00579-19","article-title":"Dynamics of the humoral immune response to a prime-boost Ebola vaccine: quantification and sources of variation","volume":"93","author":"Pasin","year":"2019","journal-title":"J Virol"},{"key":"2025020417125878000_jiae360-B20","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1073\/pnas.1209591110","article-title":"Antibodies are necessary for rVSV\/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates","volume":"110","author":"Marzi","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025020417125878000_jiae360-B21","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3390\/vaccines10040533","article-title":"Protective CD8+ T cell response induced by modified vaccinia virus Ankara delivering Ebola virus nucleoprotein","volume":"10","author":"Kupke","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"2025020417125878000_jiae360-B22","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.immuni.2021.08.007","article-title":"Functional impairment of HIV-specific CD8+ T cells precedes aborted spontaneous control of viremia","volume":"54","author":"Collins","year":"2021","journal-title":"Immunity"},{"key":"2025020417125878000_jiae360-B23","doi-asserted-by":"crossref","first-page":"e01690-18","DOI":"10.1128\/JVI.01690-18","article-title":"HIV controllers have low inflammation associated with a strong HIV-specific immune response in blood","volume":"93","author":"Hocini","year":"2019","journal-title":"J Virol"},{"issue":"Suppl 5","key":"2025020417125878000_jiae360-B24","doi-asserted-by":"crossref","first-page":"S496","DOI":"10.1093\/infdis\/jiy429","article-title":"Kinetics of soluble mediators of the host response in Ebola virus disease","volume":"218","author":"Kerber","year":"2018","journal-title":"J Infect Dis"},{"key":"2025020417125878000_jiae360-B25","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1038\/s41467-020-17489-7","article-title":"Long-lasting severe immune dysfunction in Ebola virus disease survivors","volume":"11","author":"Wiedemann","year":"2020","journal-title":"Nat Commun"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiae360\/58689845\/jiae360.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/1\/230\/58689845\/jiae360.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/1\/230\/58689845\/jiae360.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T17:17:59Z","timestamp":1738689479000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/231\/1\/230\/7714819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,16]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,7,16]]},"published-print":{"date-parts":[[2025,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiae360","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1,15]]},"published":{"date-parts":[[2024,7,16]]}}}